Table 1.
Comparison of selected attributes of patients with refractory and non-refractory myasthenia gravis.11
| Parameter | Total (n = 128) | Nonrefractory (n = 109) | Refractory (n = 19) | p value* |
|---|---|---|---|---|
| Median age at onset, year (IQR) | 55 (38–69) | 60 (42–72) | 36 (28–51) | <0.001 |
| Female | 51% | 47% | 74% | 0.03 |
| Antibody status available | 90% | 88% | 100% | |
| Anti-AChR positive | 71% | 75% | 53% | 0.05 |
| Anti-MuSK positive | 10% | 2% | 47% | <0.001 |
| Double seronegative | 19% | 23% | 0 | 0.02 |
| Thymectomy | 24% | 17% | 68% | <0.001 |
| Thymoma status available | 60% | 61% | 58% | |
| Thymomatous | 18% | 14% | 45% | 0.02 |
| Non-thymomatous | 82% | 86% | 55% |
Adapted from Suh et al.11 with permission from The Yale School of Biology and Medicine.
*
For comparison between patients with refractory and nonrefractory myasthenia gravis.
Anti-AChR positive, anti-acetylcholine receptor antibody positive; anti-MuSK positive, anti-muscle-specific tyrosine kinase antibody positive; IQR, interquartile range.